ESMO 2024 | JCOG1008: final analysis of weekly versus 3-weekly cisplatin and radiotherapy in SCCHN

Makoto Tahara • 14 Sep 2024

ESMO 2024

JCOG1008

Makoto Tahara, MD, PhD, National Cancer Center Hospital East, Kashiwa, Japan, explores the final analysis of the JCOG1008 trial (jRCTs031180135), which compared weekly versus 3-weekly cisplatin plus radiotherapy in post-operative high-risk squamous cell carcinoma of the head and neck (SCCHN). Weekly cisplatin and radiotherapy maintained non-inferiority in overall survival (OS) after 5 years with fewer acute toxicities. Relapse-free survival (RFS) and local relapse-free survival (LRFS) were also improved in the weekly regimen. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.